<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>21477698</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Barberán, José</dc:author>
<dc:description xml:lang="en">The use of modern antibiotics in clinical practice for indications that seem highly appropriate but are not approved is hampered by the lack of clinical trials. When there are no valid alternatives, the use of off-label antimicrobials is based on data obtained from microbiological activity, pharmacokinetic and pharmacodynamic profiles, experimental models, case reports and small series. Experimental models provide information on indications not investigated in clinical trials and can partly solve the inability of new drugs to demonstrate superiority over comparators. Several experimental models in osteomyelitis and implant-associated infections by methicillin-resistant Staphylococcus aureus have demonstrated that daptomycin at high doses and in combination with rifampicin have produced superior results to comparators.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2010 Dec </dc:date>
<dc:title xml:lang="es">Tratamiento actual de las infecciones por grampositivos: del modelo experimental a la experiencia clínica tras la autorización de nuevos fármacos.</dc:title>
<dc:title xml:lang="en">[Current treatment of Gram-positive infections: from experimental models to clinical experience after approval of new drugs].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
